Secondary prophylaxis for Clostridioides difficile infection for patients on non- Clostridioides difficile antibiotics: A retrospective cohort study.|https://dx.doi.org/10.1016/j.micinf.2024.105349
Fecal microbiota transplantation: current challenges and future landscapes.|https://dx.doi.org/10.1128/cmr.00060-22
Validation of clinical risk tools for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1017/ice.2024.75
Clostridioides Difficile: A Concise Review of Best Practices and Updates.|https://dx.doi.org/10.1177/21501319241249645
Fighting against Clostridioides difficile infection: Current medications.|https://dx.doi.org/10.1016/j.ijantimicag.2024.107198
Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies.|https://dx.doi.org/10.1177/08971900241248883
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.|https://dx.doi.org/10.1101/2024.04.30.591969
Offline Two-Dimensional Liquid Chromatography-Mass Spectrometry for Deep Annotation of the Fecal Metabolome Following Fecal Microbiota Transplantation.|https://dx.doi.org/10.1021/acs.jproteome.4c00022
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.|https://dx.doi.org/10.1016/j.celrep.2024.114245
Protection against Clostridioides difficile disease by a naturally avirulent C. difficile strain.|https://dx.doi.org/10.1101/2024.05.06.592814
